RussianPatents.com

Methods of producing hexahydrofuro[2, 3-b] furan-3-ol

Methods of producing hexahydrofuro[2, 3-b] furan-3-ol
IPC classes for russian patent Methods of producing hexahydrofuro[2, 3-b] furan-3-ol (RU 2464266):
Another patents in same IPC classes:
Docosahexaenoic acid ethers and their application for treatment and prevention of cardiovascular diseases Docosahexaenoic acid ethers and their application for treatment and prevention of cardiovascular diseases / 2451672
This invention relates to a compound ether of docosahexanoic acid and an alcohol, its production method and a pharmaceutical composition applied as a medication for prevention and treatment of cardiovascular diseases. The said alcohol is selected from pentanol with formula: and inositol with formula . The compound ether production method consists in transetherification of docosahexanoic acid ethyl ether with one of the said alcohols.
Method of synthesis of anticancer derivatives of (poly)aminoalkylaminoacetamide epipodofillotoxine Method of synthesis of anticancer derivatives of (poly)aminoalkylaminoacetamide epipodofillotoxine / 2450009
Invention refers to a new method for preparing anticancer preparations representing derivatives of (poly)aminoalkylaminoacetamide epipodofillotoxine of formula 1. The method implies a condensation stage of the compounds of formulae 4 and 6 in a polar aprotonic solvent without pre-protection of functional amine groups to produce a compound of formula 1, wherein in formulae 1, 4 and 6 R represents hydrogen atom or -(CH2)c-NH2, 2≤a, b, c≤5.
Carbocyclic and heterocyclic arylsulfones as γ-secretase inhibitors Carbocyclic and heterocyclic arylsulfones as γ-secretase inhibitors / 2448964
Claimed invention relates to compounds of formula (I) or to their pharmaceutically acceptable salts, in which X is selected from group, consisting of-C(R1)2-, -O-, -S-, -S(O2)-, -NR1-; each R1 is independently selected from group consisting of H and alkyl; each of R2, R3 and R4 is independently selected from group consisting of (1) H, (2) alkyl, (3) -OR5, (4) alkylene-OR5, (5) -alkylene-R6, (6) -C(O)O-alkyl, (7) - alkylene-C(O)O-alkyl, (8) -alkylene-R8, (9) -NHR5, (10) -N(R5)2, (11) alkenyl, (12) -NH-R8, (13) -NH-CH(C(O)O(C1-C6)alkyl)-alkylene-O-alkyleneR6, (14)-NHCH(C(O)O(C1-C6)aalkyl)-alkylene-OH, (15) -NH-C(O)-alkenyl and (16) -N(C1-C6alkyl)C(O)-alkenyl; or R2 and R3 or R2 and R4 or R3 and R4 together with atoms with which they are bound, form condensed 3-7-member cycloalkyl or heterocycloalkyl ring, which represents non-aromatic monocyclic ring system, which contains in ring from about 5 to about 7 atoms, and one or several atoms in ring system represent atom of element, different from carbon, for instance, nitrogen or oxygen, and said condensed cycloalkyl or heterocycloalkyl ring is not substituted or is substituted with one or several groups L3 ; and on condition that if X represents -O-, and m equals 1, then, at least, one of R2, R3 or R4 is not H; each R5 is independently selected from group consisting of (1) H, (2) (C1-C6)alkyl, (3) hydroxy-substituted alkyl, (4) R6, (5) R7, (6) -C(O)-(C1-C6)alkyl, (7) -C(O)-(C1-C6)halogenalkyl, (8) -C(O)-R6, (9) -C(O)-R7, (10) -C(O)NH-(C1-C6)alkyl, (11) -C(O)N((C1-C6)alkyl)2, in which each alkyl group is selected independently, (12) -S(O)2-(C1-C6)alkyl, (13) -S(O)2-(C1-C6)halogenalkyl, (14) -S(O)2-R6, (15) -S(O)2-R7, (16) -S(O)2-R8, (17) -alkylene-C(O)-(C1-C6)alkyl, (18) -alkylene-C(O)-(C1-C6)halogen-alkyl, (19) -alkylene-C(O)-R6, (20) -alkylene-C(O)-R7, (21) -alkylene-S(O)2-(C1-C6)alkyl, (22) -alkylene-S(O)2-(C1-C6)halogenalkyl, (23) -alkylene-S(O)2-R6, (24) -alkylene-S(O)2-R7, (25) -alkylene-S(O)2-R8, (26) -alkylene-NHC(O)-(C1-C6)alkyl, (27) -alkylene-NHC(O)-(C1-C6)halogenalkyl, (28) alkylene-NHC(O)-R6, (29) -alkylene-NHC(O)-R7, (30) -alkylene-NHS(O)2-(C1-C6)alkyl, (31) -alkylene-NHS(O)2-(C1-C6)halogenalkyl, (32) -alkylene-NHS(O)2-R6, (33) -alkylene-NHS(O)2-R7, (34) -alkylene-N(alkyl)C(O)-(C1-C6)alkyl, (35) -alkylene-N(alkyl)C(O)-(C1-C6)halogenalkyl, (36) -alkylene-N(alkyl)C(O)-R6, (37) -alkylene-N(alkyl)C(O)-R7, (38) -alkylene-N(alkyl)S(O)2-(C1-Ce)alkyl, (39) -alkylene-N(alkyl)S(O)2-(C1-C6)halogen-alkyl, (40)-alkylene-N(alkyl)S(O)2-R6, (41) -alkylene-N(alkyl)S(O)2-R7, (42) -alkylene-C(O)-NH-(C1-C6)alkyl, (43) -alkylene-C(O)-NHR6, (44) -alkylene-C(O)-NHR7, (45) -alkylene-S(O)2NH-(C1-C6)alkyl, (46) -alkylene-S(O)2NH-R6, (47) -alkylene-S(O)2NH-R7 , (48) -alkylene-C(O)-N((C1-C6)alkyl)2, in which each alkyl group is selected independently, (49) -alkylene-C(O)-N(alkyl)-R6, (50) -alkylene-C(O)-N(alkylene)-R7, (51) -alkylene-S(O)2N((C1-C6)alkyl)2, in which each alkyl group is selected independently, (52) -alkylene-S(O)2N(alkyl)-R6, (53) -alkylene-S(O)2N(alkyl)-R7, (54) -alkylene-OH, (55) -alkylene-OC(O)-NH-alkyl, (56) -alkylene-OC(O)NH-R8, (57) -alkylene-CN, (58) -R8, (59) -alkylene-SH, (60) -alkylene-S(O)2-NH-R8, (61) -alkylene-S(O)2-alkylene-R6, (62) substituted with halogen alkylene, (63) -C(O)OR8, (64) -C(O)O(C1-C6)alkyl, (65) -C(O)R8, (66) -C(O)-alkylene-O-(C1-C6)alkyl, (67) -C(O)NH2, (68) -alkylene-O-(C1-C6)alkyl, (69) -alkylene-R8, (70) -S(O)2-halogen(C1-C6)alkyl, (71) hydroxy-substituted halogen(C1-C6)alkyl, (72) -alkylene-NH2, (73) -alkylene-NH-S(O)2-R8, (74) -alkylene-NH-C(O)-R8, (75) -alkylene-NH-C(O)O-(C1-C6)alkyl, (76) -alkylene-O-C(O)-(C1-C6)alkyl, (77) -alkylene-O-S(O)2-(C1-C6)alkyl, (78) -alkylene-R6 , (79) -alkylene-R7, (80) -alkylene-NH-C(O)NH-(C1-C6)alkyl, (81) -alkylene-N(S(O)2 halogen(C1-C6)alkyl)2, and each -S(O)2 halogen(C1-C6)alkyl fragment is selected independently, (82) -alkylene-N((C1-C6)alkyl)S(O)2-R8 , (83) -alkylene-OC(O)-N(alkyl)2, and each alkyl is selected independently, (84) -alkylene-NH-(C1-C6)alkyl, (85) -C(O)-alkylene-C(O)O-(C1-C6)alkyl, (86) -C(O)-C(O)-O-(C1-C6)alkyl, (87) -C(O)-alkylene-R6, (88) -C(O)-NH-R8, (89) -C(O)-NH-R6, (90) -C(O)-NH-alkylene-R6, (91) -C(O)-alkylene-NH-S(O)2-halogen(C1-C6)alkyl, (92) -C(O)-alkylene-NH-C(O)-O-(C1-C6)alkyl, (93) -C(O)-alkylene-NH2, (94) -C(O)-alkylene-NH-S(O)2-R8, (95) -C(O)-alkylene-NH-S(O)2-(C1-C6)alkyl, (96) -C(O)-alkylene-NH-C(O)-(C1-C6)alkyl, (97) -C(O)-alkylene-N(S(O)2(C1-C6)alkyl)2, and each -S(O)2(C1-C6)alkyl fragment is elected independently, (98) -C(O)-alkylene-NH-C(O)-NH-(C1-C6)alkyl, (99) -alkylene-O-R6, (100) -alkylene-R7, (101) -C(O)OH, (102) -alkylene-N(S(O)2(C1-C6)alkyl)2, (103) -alkylene-C(O)-O-(C1-C6)alkyl, (104) halogenalkyl, (105) halogen, (106) -alkylene-C(O)-NH2, (107) =N-O-(C1-C6)alkyl, (108) =N-O-alkylene-R6, (109) =N-O-alkenyl, (110) -N-O-R6, (111) =N-NH-S(O)2-R6, (112) alkenyl, (113) =R8, (114) -O-C(O)-R9, (115) -O-C(O)-(C1-C6)alkyl, (116)-CN, R6 is selected from group consisting of unsubstituted (C6-C14)aryl, (C6-C14)aryl, substituted with one or several groups L1, unsubstituted (C5-C14)heteroaryl and (C5-C14)heteroaryl, which represents aromatic monocyclic or bicyclic system, which contains in ring from about 5 to about 9 atoms, and one or several atoms in ring system represent atom of element, different from carbon, for instance, nitrogen, oxygen or sulphur, one or in combination, substituted with one or several groups L1; R7 is selected from group consisting of unsubstituted heterocycloalkyl and heterocycloalkyl which represents non-aromatic monocyclic system, which contains in ring from about 4 to about 6 atoms, and one or several atoms in ring system represent atom of element, different from carbon, for instance, nitrogen, oxygen substituted with one or several groups L2; R8 is selected from group consisting of unsubstituted cycloalkyl and cycloalkyl substituted with one or several groups L2; A8 is selected from group consisting of (a) unsubstituted aryl, (b) aryl substituted with one or several groups L1; each group L1 is independently selected fron group consisting of halogen, alkyl, -CN, -CF3, -O-(C1-C6)alkyl, -O-(halogen(C1-C6)alkyl), -alkylen-OH (-CH2OH); each group L2 is independently selected from group consisting of (a) -OH, (b) alkyl, (c) alkyl substituted with one or several groups -OH and (d) piperidyl; each group L3 is independently selected from group consisting of -CN, =O, R5 , -OR5 ; =N-R5 and -N(R5)2; n equals 0, 1, 2 or 3; and m equals 0, 1 or 2; and on condition that in composition of substituent -OR5 fragment R5 and oxygen atom, which it is bound with, do not form group -O-O-; and on condition that in composition of substituents -OR5, =N-R5 and -NHR5 R5 are not -CH2OH, -CH2NH2, -CH2NH-alkyl, -CH2NH-aryl or -C(O)OH. Invention also relates to pharmaceutical composition, as well as to application of one or several compounds by one of ii. 1-125.
Synergist for improvement of effectiveness of biological agents against colorado potato beetle Synergist for improvement of effectiveness of biological agents against colorado potato beetle / 2448464
Improvement of effectiveness of insecticidal preparation is achieved through the use in sublethal doses of a mixture of fluorinated usnic acid (FUA) of the formula and II obtained by the reaction of (+)-usnic acid with perfluoropropene as a synergist of such insecticides. The decline of the latent period of the disease and increased mortality rate of larvae of Colorado potato beetle is marked using FUA and entomopathogenic microorganisms of Beauveria bassiana, Metarhizium anisopliae and Bacillus thuringiensis. The mixed composition of FUA at a concentration of 0.03% with a suspension of conidia of the fungus Bauveria bassiana with a titer of 3×106 conidia/ml (in vitro) and 5×106 conidia/ml (in the field) has proved to be the best in all respects.
Method of producing optically active chromene oxide compound Method of producing optically active chromene oxide compound / 2448112
Invention relates to a method of producing an optically active chromene oxide compound of formula or formula where R5, R6, R7, R8, R9, R10 and A are as described in the claim, and the absolute configuration of carbon atoms, denoted by *, denotes (R) or (S), which includes asymmetric epoxidation of a chromene compound of formula or formula with an oxidant in a solvent using optically active titanium complexes of formula formula formula and formula where R1, R2, R3 and R4 are defined in the claim, as a catalyst for asymmetric oxidation of the optically active chromene compound with high enantioselectivity and high chemical output.
Novel condensed pyrrole derivatives Novel condensed pyrrole derivatives / 2434853
Invention relates to compounds of formula (1) (lb) in which A denotes a benzene ring; Ar denotes naphthalenyl which optionally contains 1-3 substitutes independently selected from a group comprising C1-C6alkyl, C3-C7cycloalkyl, C3-C7cycloalkyl-C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, hydroxy group, C1-C6alkoxy group, halogen, heteroalkyl, heteroalkoxy group, nitro group, cyano group, amino- and mono- or di- C1-C6alkyl-substuted amino group; R1 denotes hydrogen, halogen, C1-C6alkyl, C1-C6alkoxy group, carboxy group, heteroalkyl, hydroxy group optionally substituted with heterocyclylcarbonyl-C1-C6alkyl or R1 denotes N(R')(R")-C1-C6alkyl or N(R')(R")-carbonyl- C1-C6alkyl-, in which R' and R" are independently selected from a group comprising hydrogen, C1-C6alkyl, C3-C7cycloalkyl, C3-C7cycloalkyl-C1-C6alkyl, heteroalkyl, phenyl-C1-C6alkyl; or R1 denotes R'-CO-N(R")-C1-C6alkyl, R'-O-CO-N(R")- C1-C6alkyl- or R'-SO2-N(R")- C1-C6alkyl-, in which R' and R" are independently selected from a group comprising hydrogen, C1-C6alkyl, C3-C7cyclalkyl, C3-C7cycloalkyl- C1-C6alkyl or optionally substituted phenyl; R2, R2' and R2" independently denote hydrogen, halogen, cyano group, C1-C6alkyl, halogenated C1-C6alkyl or C1-C6alkoxy group; n equals 1; and pharmaceutically acceptable salts thereof. The invention also relates to use of compounds in any of claims 1-9, as well as to a pharmaceutical composition.
Antiarrhythmic compound precursors, synthesis processes and methods of application Antiarrhythmic compound precursors, synthesis processes and methods of application / 2422447
Invention refers to compounds of formula formula (1) formula (2) or to their hydrate, solvate, salt or tautomer form where R1 independently represents H or halogen; R2 represents H or --R10-NR11R12 where R10 represents C1-C6 alkylene; R11 and R12 independently represent H, C1-C4 alkyl; and R3 independently represents H or halogen. Besides, the invention covers methods of preparing the compounds of the present invention.
Synthesis of protease inhibitor precursor Synthesis of protease inhibitor precursor / 2421459
Invention relates to a compound of formula (I) or stereoisomer thereof, or salt thereof, as well as synthesis method thereof and intermediate compounds of formulae (II) and (III) used in this method.
Methods of producing (3r, 3as, 6ar) hexahydrofuro[2,3-b]furan-3-ol Methods of producing (3r, 3as, 6ar) hexahydrofuro[2,3-b]furan-3-ol / 2421458
Invention relates to methods of producing diastereoismerically pure (3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-ol (6), as well as a novel intermediate compound (3aR,4S,6aS)-4-methoxytetrahydrofuro [3,4-b]furan-2-one (4) for use in said methods. More specifically, the invention relates to a stereo-selective method of producing diastereoisomerically pure (3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-ol, as well as methods for crystallisation of (3aR,4S,6aS)-4-methoxytetrahydrofuro[3,4-b]furan-2-one and epimerisation of (3aR,4S,6aS)-4-methoxytetrahydrofuro[3,4-b]furan-2-one to (3aR,4S,6aS)-4- methoxytetrahydrofuro[3,4-b]furan-2-one.
Products of oxidative decomposition of atorvastatin calcium Products of oxidative decomposition of atorvastatin calcium / 2412191
Invention relates to products of oxidative decomposition of atorvastatin calcium, specifically to 4-[6-(4-fluorophenyl)-6-hydroxy-1b-isopropyl-6a-phenyl-1a-phenylcarbamoylhexahydro-1,2-dioxa- 5a-azacyclopropa [a]inden-3-yl]-3-(R)-hydroxybutyric acid, phenylamide 4-(4-fluorophenyl)-2,4-dihydroxy-2-isopropyl-5-phenyl-3,6-dioxabicyclo[3.1.0]hexane-1-carboxylic acid and 4-[1b-(4-fluorophenyl)-6-hydroxy-6-isopropyl-1a-phenyl-6a-phenylcarbamoylhexahydro-1,2-dioxa-5a-azacyclopropa [a]inden-3-yl]-3-(R)-hydroxybutyric acid. The invention also relates synthesis methods thereof, based on oxidation of an atorvastatin salt.
Method of producing aldonic acids and derivatives thereof Method of producing aldonic acids and derivatives thereof / 2455296
Described is a method of producing L-gluconic acid and salt thereof, which involves treatment of aqueous solution of 6-bromo-6-deoxy-2,3-anhydro-D-manno-1,4-lactone with a base at pH equal to at least 12 and temperature from 45 to 60°C to obtain aqueous solution of L-gluconic acid. The invention also describes methods of producing 6-bromo-6-deoxy-2,3-anhydro-D-manno-1,4-lactone by reacting 2,6-dibromo-2,6-dideoxy-D-mannono-1,4-lactone with a Lewis base in a ketone solvent in the presence of catalytic amounts of water.
Method of producing capecitabine and β-anomer rich trialkylcarbonate compound used therein Method of producing capecitabine and β-anomer rich trialkylcarbonate compound used therein / 2439064
Present invention relates to method of producing capecitabine involving the following steps: 1) hydrolysis of a methylacetonide compound to obtain a triol compound of formula , 2) reaction of the triol compound with haloalkyl formate of the given formula in the presence of a mixture of pyridine and triethylamine to obtain a β-anomer rich trialkylcarbonate compound of formula , 3) glycosylation of the trialkylcarbonate compound using 5-fluorocytosine in the presence of an acid, 4) carbamylation of the obtained compound of formula using n-pentylchloroformate, followed by 5) removal of carbonate hydroxy-protective groups of the furan ring.
Methods of producing (3r, 3as, 6ar) hexahydrofuro[2,3-b]furan-3-ol Methods of producing (3r, 3as, 6ar) hexahydrofuro[2,3-b]furan-3-ol / 2421458
Invention relates to methods of producing diastereoismerically pure (3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-ol (6), as well as a novel intermediate compound (3aR,4S,6aS)-4-methoxytetrahydrofuro [3,4-b]furan-2-one (4) for use in said methods. More specifically, the invention relates to a stereo-selective method of producing diastereoisomerically pure (3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-ol, as well as methods for crystallisation of (3aR,4S,6aS)-4-methoxytetrahydrofuro[3,4-b]furan-2-one and epimerisation of (3aR,4S,6aS)-4-methoxytetrahydrofuro[3,4-b]furan-2-one to (3aR,4S,6aS)-4- methoxytetrahydrofuro[3,4-b]furan-2-one.
Derivatives of phenylglycine, method for their preparing, intermediate compounds, pharmaceutical composition and method for treatment Derivatives of phenylglycine, method for their preparing, intermediate compounds, pharmaceutical composition and method for treatment / 2268257
Invention relates to new derivatives of phenylglycine of the formula (I) , to their hydrates or solvates, and/or to physiologically acceptable salts and/or physiologically acceptable esters possessing inhibitory effect on amidolytic activity of the complex factor VIIa/tissue factor that can be used for therapeutic and/or prophylactic treatment of diseases, for example, thrombosis. In the formula (I) R1 means (C1-C6)-alkyl; R2 means hydrogen atom, hydroxy-(C1-C6)-alkoxy-, (C1-C6)-alkoxycarbonyloxy-, (C1-C6)-alkoxy-group or halogen-(C1-C6)-alkoxycarbonyloxy-(C1-C6)-alkoxy-group; R3 means hydrogen atom, (C1-C6)-alkoxy- or heterocycloalkyloxy-group wherein heterocycloalkyl group means 5-6-membered ring comprising a heteroatom taken among nitrogen and oxygen atom; R4 means hydrogen atom or ester residue that is cleaved off under physiological conditions. R5 means hydrogen atom, hydroxy-group, (C1-C6)-alkoxycarbonyl, halogen-(C1-C6)-alkoxycarbonyl, (C6)-aryloxycarbonyl,(C6)-arylalkoxycarbonyl, (C1-C6)-alkoxy-(C1-C6)-alkoxy(C1-C6)-alkoxycarbonyl, (C3-C6)-cycloalkyloxycarbonyl, (C2-C6)-alkynyloxycarbonyl, 5-methyl-2-oxo[1,3]dioxol-4-yl-methoxycarbonyl, (C6)-arylcarbonyloxy-, (C1-C6)-alkylaminocarbonyloxy-group, (C1-C6)-alkylcarbonyl, arylcarbonyl, arylaminocarbonyl or heteroarylcarbonyl wherein heteroaryl represents 5-6-membered ring comprising nitrogen atom the cycle; X means atom F, Cl or Br. Also, invention relates to a method for preparing compounds, intermediates substances and pharmaceutical composition and a method for treatment.
Aromatic diketone derivatives, methods for production thereof and uses as pharmaceuticals Aromatic diketone derivatives, methods for production thereof and uses as pharmaceuticals / 2252211
Invention relates to new aromatic diketone derivatives of formula I
Therapeutic agent for diabetes Therapeutic agent for diabetes / 2174114
The invention relates to a new therapeutic drug for diabetes and includes the compound of the formula I: R1-C(O)-C(R2')(R2)-X-C(O)-R3where X represents a group of formula-C(R4)(R5)-, -N(R6)-, -O-; where R4is a hydrogen atom, a C1-C5alkyl, carboxy, phenyl, C2-C5acyl, C2-C5alkoxycarbonyl, R5is a hydrogen atom, a C1-C5alkyl; R6is hydrogen; R1is phenyl, optionally substituted C1-C5by alkyl, hydroxy, hydroxyalkyl, C2-C6alkenyl, acyl, carboxy, teinila, C3-C7cycloalkyl; biphenyl, optionally substituted C1-C5the alkyl or hydroxy; naphthyl; terphenyl; C3-C7cycloalkyl, optionally substituted C1-C5the alkyl or phenyl; optionally substituted C1-C5alkyl; pyridyl; sensational; substituted; indanyl; fluorenyl or group; R2is hydrogen, C1-C5alkyl, optionally substituted by carboxy; R2'is hydrogen; R3- C1-C5alkyl, optionally substituted by phenyl or C1-C4alkoxy, C1-C4alkoxy; hydroxy; phenyl; C3-C7</ is the group -(CH2)2-; R2and R5taken together, form a simple bond or-CH2-, - (CH2)3-, -(CH2)4-; R2, R2', R4and R5taken together form =CH-CH=CH-CH=; R2' and R3taken together form a-CH(R8)-OH, -CH(R8)-CH(R9)-, -CH(R8)NH; R8and R9is hydrogen, and pharmaceutically acceptable salts
Derivatives of tetrahydrofuran, the retrieval method and the method of combating fungi Derivatives of tetrahydrofuran, the retrieval method and the method of combating fungi / 2079274
The invention relates to a new means of plant protection
Aromatic diketone derivatives, methods for production thereof and uses as pharmaceuticals Aromatic diketone derivatives, methods for production thereof and uses as pharmaceuticals / 2252211
Invention relates to new aromatic diketone derivatives of formula I
Derivatives of phenylglycine, method for their preparing, intermediate compounds, pharmaceutical composition and method for treatment Derivatives of phenylglycine, method for their preparing, intermediate compounds, pharmaceutical composition and method for treatment / 2268257
Invention relates to new derivatives of phenylglycine of the formula (I) , to their hydrates or solvates, and/or to physiologically acceptable salts and/or physiologically acceptable esters possessing inhibitory effect on amidolytic activity of the complex factor VIIa/tissue factor that can be used for therapeutic and/or prophylactic treatment of diseases, for example, thrombosis. In the formula (I) R1 means (C1-C6)-alkyl; R2 means hydrogen atom, hydroxy-(C1-C6)-alkoxy-, (C1-C6)-alkoxycarbonyloxy-, (C1-C6)-alkoxy-group or halogen-(C1-C6)-alkoxycarbonyloxy-(C1-C6)-alkoxy-group; R3 means hydrogen atom, (C1-C6)-alkoxy- or heterocycloalkyloxy-group wherein heterocycloalkyl group means 5-6-membered ring comprising a heteroatom taken among nitrogen and oxygen atom; R4 means hydrogen atom or ester residue that is cleaved off under physiological conditions. R5 means hydrogen atom, hydroxy-group, (C1-C6)-alkoxycarbonyl, halogen-(C1-C6)-alkoxycarbonyl, (C6)-aryloxycarbonyl,(C6)-arylalkoxycarbonyl, (C1-C6)-alkoxy-(C1-C6)-alkoxy(C1-C6)-alkoxycarbonyl, (C3-C6)-cycloalkyloxycarbonyl, (C2-C6)-alkynyloxycarbonyl, 5-methyl-2-oxo[1,3]dioxol-4-yl-methoxycarbonyl, (C6)-arylcarbonyloxy-, (C1-C6)-alkylaminocarbonyloxy-group, (C1-C6)-alkylcarbonyl, arylcarbonyl, arylaminocarbonyl or heteroarylcarbonyl wherein heteroaryl represents 5-6-membered ring comprising nitrogen atom the cycle; X means atom F, Cl or Br. Also, invention relates to a method for preparing compounds, intermediates substances and pharmaceutical composition and a method for treatment.
Methods of producing (3r, 3as, 6ar) hexahydrofuro[2,3-b]furan-3-ol Methods of producing (3r, 3as, 6ar) hexahydrofuro[2,3-b]furan-3-ol / 2421458
Invention relates to methods of producing diastereoismerically pure (3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-ol (6), as well as a novel intermediate compound (3aR,4S,6aS)-4-methoxytetrahydrofuro [3,4-b]furan-2-one (4) for use in said methods. More specifically, the invention relates to a stereo-selective method of producing diastereoisomerically pure (3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-ol, as well as methods for crystallisation of (3aR,4S,6aS)-4-methoxytetrahydrofuro[3,4-b]furan-2-one and epimerisation of (3aR,4S,6aS)-4-methoxytetrahydrofuro[3,4-b]furan-2-one to (3aR,4S,6aS)-4- methoxytetrahydrofuro[3,4-b]furan-2-one.

FIELD: chemistry.

SUBSTANCE: invention relates to a method of producing a compound of formula (V) which can be used in pharmaceutical industry . The method involves reaction of a compound of formula (II) with a compound of formula (III) in the presence of a titanium salt of formula Ti(Hal)n(OR)4-n, where Hal is a halogen radical, n equals 0, 1, 2 or 3, R is an alkyl or arylalkyl, and subsequent reaction of the reaction product with an alcohol of formula (IV), where R1 and R2 denote alkyl or arylalkyl, where the aryl is phenyl or naphthyl.

EFFECT: novel efficient method of producing compounds of the given formula using novel intermediate compounds is disclosed.

16 cl, 9 ex

 

The present invention relates to methods for hexahydrofuro[2,3-b]furan-3-ol and especially its enantiomer (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol, as well as some new intermediate products for use in such methods.

(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-oxyradical is an important part pharmacological present in the structure of retroviral protease inhibitors, such as inhibitors described Glosh et al. in J. Med. Chem. 1996, 39(17), 3278-3290 and inhibitors described in WO 95/24385, WO 99/65870, WO 99/67254, WO 99/67417, WO 00/47551, WO 00/76961, WO 01/25240, US 6127372 and EP 0715618. These publications is incorporated herein by reference. One such protease inhibitor that is approved in the US for clinical use in the treatment of retroviral infections in humans and has the above structural part, is a compound that has allowed USAN name darunavir and chemical name (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-silt ether [(1S,2R)-3-[[(4-AMINOPHENYL)sulfonyl](2-methoxypropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]carbamino acid and the structure of the formula (And)

An important precursor in the synthesis of protease inhibitors described above and containing hexahydrofuro[2,3-b]furan-3-oxyradical, is the connection hexahydrofuro[2,3-b]furan-3-ol of the formula (I)

Despite the fact that what hexahydrofuro[2,3-b]furan-3-ol has three stereogenic center and theoretically there should be eight different stereoisomers, believe that there are only four stereoisomer. This is due to the rigidity of the structure of the bicyclic ring hexahydrofuro[2,3-b]furan-3-Ola, which makes him the TRANS-condensed isomers to be thermodynamically unfavorable. Only the stereoisomers having the CIS-condensed configuration, are thermodynamically stable, reducing the number of stereoisomers hexahydrofuro[2,3-b]furan-3-ol to endo - and Exo-diastereoisomer, and each comprises a pair of enantiomers, as shown below

More specifically, for obtaining such protease inhibitors containing enantiomeric (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-oxyradical, such as the protease inhibitor darunavir, related to the above (3R,3aS,6aR)-enantiomer of formula (Ia), is especially applicable

Due to the potential importance of the above protease inhibitors and the resulting need for the production of these compounds on a commercial scale, in the literature there have been numerous suggestions on ways you can get the above compounds of formulas (I) and (Ia).

Many of these proposals were included on the education structure of bicyclic besturen, from acyclic precursors, for example including intermediate education lactoovo the intermediate and then the recovery and cyclization of such methods, as the methods of preparation, are described in WO 03/022853, US 2004/0162340, WO 2004/033462, US 6867321, WO 2005/095410, and Ghosh et al., J. Org. Chem. 2004, 69, 7822-7829. These methods include a relatively large number of stages, and in some cases education nitromethylene intermediate compounds, requiring the use of nitromethane, which is harmful reagent. Another approach, described in WO 02/060905, involves the reaction of 2,3-dihydrofuran with alkylphosphonyl with the formation of a derivative of 2-alkyloxyaryl, which then cyclist in the presence of radiation. The use of radiation, however, is unsuitable for practical application of the method on an industrial scale. The use of radiation is also required in the method described in WO 03/024974, in which the furan is subjected to reaction with a carbonyl derivative in the presence of radiation. In WO 2004/002975 described method coming from 2,3-dihydrofuran, which is subjected to the reaction, for example, with harpokrates ether to effect the introduction of glyoxylate group at the 3-position of the furan ring and then restore with the formation of 1,2-dihydroxyethylene side chain and subsequent processing, for example, halogenides the m agent with the formation of compounds 3A-halogenerator[2,3-b]furan-3-ol, then restore. This method also has the disadvantage that require multiple steps when receiving from the source of furan, which is uneconomical for industrial scale.

A similar approach is proposed by Ghosh et al. in Tetrahedron Letters 40 (1999) 1083-1086, comprising the reaction of 2,3-dihydrofuran with acylglycerol and titanium tetrachloride to obtain the intermediate oxonium ion, which is then subjected to reaction with a nucleophile, while receiving derivatives of 3-(β-carboethoxy-α-hydroxymethyl)-2-substituted tetrahydrofuran. Examples of such nucleophiles include semiprozine and methanol. In only described example, the mixture of ethylglycol and 2,3-dihydrofuran in dichloromethane was added to a solution of titanium tetrachloride in dichloromethane at -78°C and was stirred for one hour. To the mixture at -78°C was added allyltrimethylsilane and the resulting mixture was stirred at a temperature of from -78°C to 23°C for one hour. The reaction extinguished aqueous solution of sodium bicarbonate and was extracted with ethyl acetate and the combined organic layers were dried, concentrated and then purified flash chromatography. This method suffers from some drawbacks, such as very low reaction temperature -78°C, which is almost impossible for the reaction to industrial scale is A. In addition, the authors of the present invention found that the use of the method with titanium tetrachloride, described by Ghosh et al., causes problems in subsequent processing to ensure effective removal of compounds of titanium, and the removal of the titanium salt is essential to avoid impurities and adverse reactions in the subsequent stages.

The objective of the invention is the provision of a new and improved synthesis for the preparation of hexahydrofuro[2,3-b]furan-3-ol. An additional object of the invention is the provision of such a synthesis, which apply easily accessible and cheap source connection and applied reaction conditions, which are easily achievable by synthesis on an industrial scale. An additional object of the invention is the provision of a suitable method of obtaining derivatives of 3-(β-carboethoxy-α-hydroxymethyl)-2-substituted tetrahydrofuran and their analogues. An additional object of the present invention is the provision of new and suitable intermediate products which are applicable in the synthesis of hexahydrofuro[2,3-b]furan-3-ol. The next task of the invention is to provide a new and improved synthesis of (3R,3aR,6aR)-hexahydrofuro[2,3-b]furan-3-ol, applicable when receiving antiretroviral protease inhibitors.

Found that the use of certain salts ti is Ana, different from the titanium tetrachloride used Ghosh et al. in the above-described method offers several advantages described below. The authors of the present invention has also been found that purification of the crude product 3-(β-carboethoxy-α-hydroxymethyl)-2-substituted tetrahydrofuran can be improved by the use of some agents such as water-soluble complexing agents (for example, Rochelle salt or diethanolamine), for damping the reaction and removal of salts of titanium, which can be harmful to subsequent stages. Thus, the use of water-soluble complexing agent instead of sodium bicarbonate, described by Ghosh et al., leads to a significant improvement in the quality of the resulting product.

Application of the above method and the subsequent conversion of the resulting product, 3-(β-carboethoxy-α-hydroxymethyl)-2-substituted tetrahydrofuran provides a suitable synthetic route for obtaining hexahydrofuro[2,3-b]furan-3-ol and (3R,3aR,6aR)-enantiomer with a relatively small number of stages compared with the methods of the prior art and using low-cost raw materials and the reaction conditions that ensure the final product and intermediate products in good yield and purity.

According to one distinctive feature of nastoyascheevremya the authors of the invention, a method for obtaining compounds of formula (V), which comprises the reaction of 2,3-dihydrofuran formula (II) with a derivative of glyoxylate formula (III) in the presence of a titanium salt of the formula Ti(Hal)n(OR)4-nin which Hal represents a halogen radical, n is 0, 1, 2 or 3 and R represents an alkyl or arylalkyl, and subsequent reaction of the resulting reaction product with an alcohol of the formula (IV) with the formation of the compounds of formula (V)

in which R1represents an alkyl or arylalkyl and R2represents an alkyl or arylalkyl.

Derived glyoxylate formula (III) is preferably a compound in which R1represents a C1-4alkyl group, especially ethyl group, or phenyl-C1-4alkyl group, especially a benzyl group. Salt of titanium is preferably the salt of the formula Ti(Hal)n(OR)4-nin which Hal represents a chlorine atom or bromine, especially chlorine atom, and R represents a C1-4alkyl group, for example through group, preferably ISO-propyl group, or arylalkyl group, for example phenyl-C1-4alkyl group, especially benzyl, and n is 1 or 2, especially 2; in particular, the preferred salt of titanium for use according to the present invention is TiCl2(OiPr)2. It will be clear that such titanium salt mo the ut to be formed in situin the reaction mixture, for example, by reaction of a suitable titanium halide with a suitable connection Ti(OR)4. Formed by the specific salt will depend on the number of connections Ti(OR)4added to the halide of titanium, for example, adding one-third of the equivalent compound Ti(OR)4will lead to the formation of compound TiHal3(OR). The above preferred salt TiCl2(OiPr)2you can get thein situthe addition of TiCl4and Ti(OiPr)4to the reaction mixture. The method of obtaining the above connection TiCl2(OiPr)2described Mikami et al., J. Am. Chem. Soc., 1990, 112, 3949-3954. The method of obtaining TiCl(OiPr)3described by Reetz et al., Chemische Berichte, 1985, 118, 1421-1440. Similarly, you can obtain other compounds of the formula Ti(Hal)n(OR)4-n.

Found that usually requires the presence of at least one group Hal in connection titanium, because the way how it was discovered, is less effective if you use a compound of the formula Ti(OR)4. In connection titanium n therefore, preferably is 1, 2 or 3. The compound of the formula Ti(OR)4usually used in combination with titanium tetrachloride to form a compound of the formula Ti(Hal)n(OR)4-nin which n is 1, 2 or 3.

Found that the application of the above titanium compounds is particularly suitable compared to Ter the chloride of titanium, used Ghosh et al., since the latter salt is unstable, corrosive liquid, whereas the titanium compounds used in the method according to the invention are generally stable solids, and therefore much more suitable for use with an industrial way. Also, found that the use of titanium tetrachloride described by Ghosh et al., leads to unacceptably high residual amounts of titanium by-products in the reaction mixture, which can cause a later stage of the synthesis hexahydrofuro[2,3-b]furan-3-ol not be holding or have very low outputs.

The alcohol of formula (IV) is preferably1-4alkanol, such as methanol, ethanol or propanol, especially isopropanol, or phenyl-C1-4alkanol, such as benzyl alcohol.

As the initial reaction of 2,3-dihydrofuran with derivative glyoxylate and subsequent reaction with an alcohol of the formula (IV) is usually carried out in an organic solvent, preferably an aprotic solvent such as dichloromethane, ethyl acetate, 1,2-dichloroethane, tetrahydrofuran (THF), or a 2-methyltetrahydrofuran.

These reactions are suitably carried out at a temperature of at least -20°C, preferably at least -10°C. and especially at least -5°C, preferably is conducted at room temperature. The use of such temperatures is in contrast with the use of temperature -78°C, described by Ghosh et al. in Tetrahedron Letters to the method specified above. First, more elevated temperatures used according to the present invention, are significantly more suitable for carrying out the method on an industrial scale.

Another advantage of the method according to the invention in comparison with the method described by Ghosh et al., as was found by the authors of the present invention is that the connection of titanium can be used in less than stoichiometric amount, for example 0.5 equivalent or less, whereas in method Ghosh requires the use of an equivalent amount of the titanium compounds. The use of smaller quantities of titanium is more cost-effective and causes fewer side products that you want to delete, and the way the authors of the invention is therefore suitable from the point of view of environmental protection.

After completion of the reaction with the alcohol of formula (IV), the reaction mixture is usually treated with an alkaline reagent to absorb or termination of any additional reactions and formation of side products, and the alkaline reagent usually provides pH 8-11, preferably about 10. In the method of Ghosh et al. (Tetrahedron Letters) for damping the reaction is used an aqueous solution of bicarbonate soda who I am. However, the inventors found that the use of water-soluble complexing agent as an alternative quenching reagent provides significantly improved handling. As water-soluble complexing agent can be used as ionic compounds, such as signatory salt (tartrate tetrahydrate sodium-potassium), and neutral organic molecules, such as diethanolamine. So, the addition of Rochelle salt or diethanolamine in an aqueous solution to the organic reaction mixture obtained in the above way, quench the reaction and allows any residual connection titanium easily separated in the aqueous phase and leaves the organic phase containing the desired compound of formula (V), which usually contains less than 5 ppm of titanium compounds. The resulting compound of formula (V) obtained as a mixture of stereoisomeric forms and can be used as such for the next stage in the synthesis hexahydrofuro[2,3-b]furan-3-ol.

The above method, starting with 2,3-dihydrofuran, provides the desired compounds of formula (V) with high or even quantitative outputs and good quality with the use of reagents that are readily available from commercial sources, and reaction conditions that can be applied on an industrial scale.

Term is n "alkyl" alone or in combination with any other term includes, except when specified otherwise, to a saturated aliphatic hydrocarbon radical with unbranched or branched chain, or in the case when there is at least three carbon atoms, a cyclic saturated aliphatic hydrocarbon radicals containing 1-10 carbon atoms, preferably 1-8 carbon atoms, more preferably 1-6 carbon atoms, or more preferably 1-4 carbon atoms. Examples of such radicals include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, n-hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.

The term "aryl", alone or in combination with any other term, refers to carbocyclic aromatic part and includes monocyclic, bicyclic and other polycyclic radicals. Examples of aryl radicals include, but are not limited to, phenyl and nattily radicals.

The term "halogen" refers to fluorine atom, chlorine, bromine or iodine.

The term "stereoisomeric forms used here, defines all possible isomers formed from the same atoms connected in the same sequence of relationships, but having different three-dimensional structures that are not aplaycasinogameh, which may have compound of the present invention. If not specified or not specifically mentioned, the chemical designation of compounds comprises a mixture of all possible stereochemical isomeric forms, which may be of the specified connection. This mixture may contain all of the diastereomers and/or enantiomers of the basic molecular structure of the compounds. It is assumed that, except when otherwise noted, all stereoisomeric forms of the compounds used in the present invention, as in the pure (individual) form or in mixture with each other, included in the scope of the present invention.

Pure stereoisomeric forms of these compounds, i.e. when you specify a specific stereoisomeric form, is defined as isomers, essentially free from other enantiomeric or diastereoisomeric forms of the same basic molecular structure of these compounds or intermediates. In particular, the term "stereoisomer pure" refers to compounds or intermediate products having a stereoisomeric excess of at least 80% (i.e. at least 90% of one isomer and a maximum of 10% of the other possible isomer) up to a stereoisomeric excess of 100% (i.e. 100% of one isomer and no other isomer), more specifically, compounds having a stereoisomeric excess of 90% to 100%,even more specifically, having a stereoisomeric excess of from 94% to 100%, and most specifically, having a stereoisomeric excess of from 97% to 100%.

Pure stereoisomeric forms of these compounds can be obtained by applying known in this field techniques. For example, the enantiomers can be separated from each other by the selective crystallization of their diastereomeric salts with optically active acids. Alternatively, the enantiomers can be divided chromatographic methods using chiral stationary phases. These pure stereochemical isomeric form can also be obtained from the corresponding pure stereochemical isomeric forms of the appropriate starting compounds, provided that the reaction proceeds stereoselective. If you want a specific stereoisomer, the specified connection is preferably synthesized by stereoselective methods of getting. In these methods are mainly applied enantiomerically pure source materials.

The resulting compound of formula (V)obtained above, can be applied at the next stage of the synthesis hexahydrofuro[2,3-b]furan-3-ol without division or allocation of its stereoisomers.

The above compounds of formula (V), except for those compounds in which R1represents methyl or ethyl and R2is the Wallpaper methyl, are new compounds, and therefore, the inventors proposed as an additional characteristic of the invention the compounds of formula (Va)

and their stereoisomeric forms and racemic mixtures,

in which R1represents an alkyl or arylalkyl and R2represents an alkyl or arylalkyl, provided that when R2represents methyl, R1is not the stands or ethyl. R1preferably represents C1-4alkyl group such as propyl, especially isopropyl, or phenyl-C1-4alkyl group, especially a benzyl group. R2preferably represents C1-4alkyl group such as ethyl or propyl, especially isopropyl, or phenyl-C1-4alkyl group, such as benzyl. The compounds of formula (V)in which R1represents ethyl or methyl and R2represents methyl, described by Ghosh et al. in Tetrahedron Letters 40 (1999) 1083-1086, above.

The compounds of formula (V) are thus applicable as intermediates in obtaining the compounds of formula (I). Especially applicable compound of formula (V) is acylhydrolase-(2-isopropoxypyridine-3-furanyl)acetate.

According to an additional characteristic of the present invention the inventors have proposed a way to floor the treatment of compounds of formula (VI), which includes the restoration of the compounds of formula (V) with the formation of the compounds of formula (VI)

The recovery of the compounds of formula (V) is usually carried out using hydride reducing agent, such as alkali metal borohydride such as lithium borohydride, sodium borohydride, potassium borohydride, acetoxyvalerenic sodium, triacetoxyborohydride sodium or cyanoborohydride sodium, reducing agent-based aluminum hydride, such as sociallyengaged, DibalH (diisobutylaluminium) or hydride aluminum, or zinc borohydride. Alternatively, the recovery can be performed by catalytic hydrogenation. The hydrogenation can be carried out with the use of a heterogeneous catalyst, such as activated Nickel catalyst, such as catalyst, commercially available from Degussa as IN 111W, activated Nickel catalyst doped with molybdenum or a combination of chrome/iron, such as catalyst, commercially available from Degussa as VK 113W, or activated copper catalyst, such as catalyst, commercially available from Degussa as W. The hydrogenation can also be carried out with the use of a homogeneous catalyst, such as ruthenium, according to the method of Milstein, ACIE 2006, 45, 1113. Recovery can also be performed by hydrosilation, for example, with p the physical alteration of polymethylhydrosiloxane (PMHS) or triethylsilane, for example, in combination with a catalyst Zn(II) (Mimoun, J. Org. Chem., 1999, 64, 2582-2589, ruthenium catalyst (Fuchikami et al., Tetrahedron Letters, 42 (2001), 2149-2151), tetrabutylammonium fluoride (TBAF or Triton B) (Lawrence et al., Synlet, 1997, 989-991), potassium fluoride or cesium fluoride (Coriu et al., Synthesis, 1982, 981 and 1981, 558) or the catalyst is titanium (IV) (Buchwald et al., J. Org. Chem. 1995, 60, 7884-7890).

Sodium borohydride is particularly preferred as the reducing agent. Recovery is usually carried out in an organic solvent, conveniently in a polar solvent such as ethanol or tetrahydrofuran. When used borhydride reducing agent, after the recovery is completed, it is desirable to extinguish the reaction of the complexing compound to form a complex with any residual boron compound in the reaction mixture and in order to avoid additional adverse reactions and formation of undesirable side products. The inventors have discovered that treatment of the reaction mixture diethanolamine, for example, in the form of its hydrochloride as a reagent for damping provides especially good results in terms of purity desired in the final product. Alternative to extinguish the reaction is predominantly possible to use the ammonium chloride. The resulting compound of formula (VI) are obtained in the form of a mixture of stereoisomeric forms and it can be used the AK itself for the next stage in the synthesis hexahydrofuro[2,3-b]furan-3-ol.

The above compounds of formula (VI) are new compounds, and therefore, the inventors proposed as an additional characteristic of the invention the compounds of formula (VI)

and their stereoisomeric forms and racemic mixtures,

in which R1represents an alkyl or arylalkyl, preferably1-4alkyl group such as methyl, ethyl or propyl, especially isopropyl, or phenyl-C1-4alkyl group, such as benzyl.

Particularly preferred new compound of the formula (VI) is 1-(2-isopropoxypyridine-3-furanyl)-1,2-ethanediol.

Thus, the compounds of formula (VI) are used as intermediates in the synthesis of compounds of formulas (I) and (Ia).

According to an additional characteristic of the present invention the inventors proposed a method of obtaining the compounds of formula (I), which contains the cyclization of the compounds of formula (VI) with the formation of the compounds of formula (I)

in which R2preferably represents C1-4alkyl group such as methyl, ethyl or propyl, especially isopropyl, or phenyl-C1-4alkyl group, such as benzyl.

The cyclization of the compounds of formula (VI) can be performed, for example, by treatment with an acid, usually a strong proton acid is one such as hydrochloric acid, p-toluensulfonate acid, methanesulfonate acid, camphorsulfonic acid, resin amberlyst, TFA, p-bromobenzophenone acid or acetic acid. The reaction is usually carried out in an organic solvent, for example a polar solvent, such as tetrahydrofuran, dichloromethane, ethyl acetate, ethanol, methanol or acetone, suitably at a temperature from -20°C to 50°C. When using tetrahydrofuran, the preferred temperature is the temperature from 40°to 50°, preferably 45°C. To neutralize the reaction mixture and the completion of the reaction add a base, such as triethylamine or pyridine. The method leads to the formation of a mixture of two diastereoisomers formula (I), namely endo-diastereoisomer containing 3R,3aS,6aR and 3S,3aR,6aS-enantiomers, and Exo-diastereoisomer containing 3S,3aS,6aR - and 3R,3aR,6aS-enantiomers above. Two diastereoisomer you can easily divide the conventional manner, for example by chromatography on silica gel using a mixture of petroleum ether/ethyl acetate (1/9) as eluent.

After separation of the above diastereoisomers endo-diastereoisomer can be applied directly when receiving protease inhibitors, requiring stereoisomeric this part, if necessary, after the separation of its constituent enantiomers,accepted way, for example, according to the method described by Ghosh et al. in Tetrahedron Letters, Vol. 36, No. 4, 505-508, 1995, or WO 02/060905, acylation, for example, acid chloride or anhydride of the acid, conveniently in an aprotic solvent such as tetrahydrofuran or dichloromethane, in the presence of a base such as sodium carbonate or triethylamine. The resulting mixture of esters are then subjected to reaction with a suitable astraslim enzyme, such as lipase Ps30, under conditions that allow the course of the reaction is primarily one of racemic esters with the formation of a mixture of alcohol predominantly one enantiomer and the remaining unreacted complex ester of the corresponding mainly the other enantiomer. The mixture of alcohol and ether complex can then divide the conventional manner, for example by chromatography on silica gel. Enantiomeric unreacted ester can be converted into the corresponding alcohol, for example, by reaction with methyllithium in tetrahydrofuran.

If desired, Exo-diastereoisomer can be turned into endo-diastereoisomer conventional manner, for example, as described by Ghosh et al. in J. Org. Chem. 2004, 69, 7822-7829, the sequence of oxidation/restore, including the intermediate formation of a ketone of the formula (I')

Thus, according to the above method of Ghosh et al., Exo-d is stereoisomer oxidized to the ketone of the formula (I') perruthenate of tetrapropylammonium (TRR) and 4-methylmorpholine-N-oxide (NMO) and the resulting ketone restore, for example, hydride regenerating agent such as sodium borohydride, in an organic solvent, for example a polar solvent, such as ethanol, thus obtaining the corresponding endo-diastereoisomer. Alternatively, the above oxidation can be performed by the system NaOCl/1-oxide 2,2,6,6-tetramethylpiperidine (TAMRA).

It should be clear that the above method of oxidation and reduction can also be carried out on the basis of a mixture of endo - and Exo-forms, which thus avoids the need for any pre-separation of diastereoisomers.

According to an additional characteristic of the invention the inventors proposed a method of obtaining hexahydro[2,3-b]furan-3-ol, which includes the following stages:

a) reaction of 2,3-dihydrofuran formula (II) with glyoxylate derivative of the formula (III) in the presence of a titanium salt of the formula Ti(Hal)n(OR)4-nin which n is 0, 1, 2 or 3 and R represents an alkyl or arylalkyl, and subsequent reaction of the resulting reaction product with an alcohol of the formula (IV) with the formation of the compounds of formula (V)

in which R1represents an alkyl or arylalkyl and R2represents an alkyl or arylalkyl, and

b) recovering the resulting compound of formula (V) with the formation connected to the I of the formula (VI)

and

(C) cyclization of the compounds of formula (VI) with the formation of the compounds of formula (I)

and, if desired, then (i) the separation of the formed compounds of formula (I) for separation of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol of the formula (Ia)

and/or

(ii) oxidizing the resulting compound of formula (I) with the formation of the compounds of formula (I')

and then restore the compounds of formula (I') in the endo-isomer of compounds of formula (I).

Compounds of formula (I) and (Ia) are particularly applicable when getting medicines. According to a preferred variant implementation of the present compounds of formulas (I) and (Ia) are used as precursors upon receipt of antiviral drugs, in particular drugs against HIV, more specifically, HIV protease inhibitors.

Compounds of formula (I) and (Ia) and all intermediate products leading to the formation of these compounds are of particular interest when receiving HIV protease inhibitors, as described by Ghosh et al. Bioorganic & Medicinal Chemistry Letters 8 (1998) 687-690 and WO 95/24385, WO 99/65870, WO 99/67254, WO 99/67417, WO 00/47551, WO 00/76961, WO 01/25240, US 6127372 and EP 0715618, all of which are incorporated herein by reference, and especially the following HIV protease inhibitors:

(3R,3S,6aR)-hexahydrofuro[2,3-b]furan-3-silt ether [(1S,2R)-3-[[(4-AMINOPHENYL)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]carbamino acid, that is, the above darunavir (inhibitor 1 protease HIV);

(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-silt ether [(1S,2R)-2-hydroxy-3-[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]carbamino acid (2 inhibitor of HIV protease and

(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-silt ether [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulphonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]carbamino acid (inhibitor 3 protease HIV) or any of their pharmaceutically acceptable additive salts.

Thus, the present invention also relates to inhibitors 1, 2 or 3 HIV protease or any pharmaceutically acceptable salts or prodrugs obtained with the use of the compounds of formula (I)obtained according to the present invention in the chemical synthesis of these HIV protease inhibitors. Such chemical synthesis described in the literature, for example, in the above patent and literature references.

The compound of the above formula (Ia) can be applied after formation of the activated derivative for the synthesis of inhibitor 1 protease, i.e. darunavir above formula (A), as described, for example, in WO2005/063770, the contents of which are incorporated herein by reference, in the following way, which contains

(i) the introduction of isobutylamine in the compound of formula (I)

where

PG is aminosidine group;

R1represents hydrogen or C1-6alkyl;

(ii) the introduction of p-nitrophenylacetylene group in the resulting compound of stage (i);

(iii) the restoration of the nitro group of the resulting compound of stage (ii);

(iv) removing the protecting formed at the connection stage (iii), and

(v) a combination formed of the connection stage (iv) with (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-alprozolam with the formation of the above compounds (A).

In one embodiment, the present invention relates to a method for obtaining compounds of formula (A), characterized in that the method comprises a stage of introduction of isobutylamine in the compound of formula (I')

obtaining the compounds of formula (2')

the introduction of p-nitrophenylacetylene group in the compound of the formula (2') to obtain the compounds of formula (3')

nitrogroup reduction of compounds of formula (3') to obtain the compounds of formula (4')

remove protection from the compounds of formula (4') to obtain the compounds of formula (5)

combinations of the compounds of formula (5) with (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-alprozolam with the formation of compound (A).

The compound of formula (1)

The compound of formula (1) is

where

PG is aminosidine group;

R1represents hydrogen or C1-6alkyl.

Compound of formula (1) preferably is a compound of formula (1'), as shown below, where PG represents a tert-butyloxycarbonyl or “Boc” and R1represents hydrogen. Compounds of formulas (1) and (1') are commercially available and can be obtained in several ways available in the literature, for example, as described in WO95/06030 (Searle & Co.), as described Kaneka Corporation in EP 0754669, EP 1029856 and EP 1067125, and as described Ajinomoto KK in EP 1081133 and EP 1215209.

The compound of the formula (2)

The compound of formula (1) is subjected aminating the epoxide with obtaining the compounds of formula (2).

Used here, the term “amination” refers to the way in which the primary amine, isobutylamine injected into the organic molecule of formula (1). Amination of the compounds of formula (1) can be done in several ways available in the literature, for example, as described in WO95/06030, which is described here as a reference.

In a preferred embodiment, the compound of formula (1') is subjected to reaction with isobutylamine with obtaining the compounds of formula (2').

<>

Amination of epoxides is described, for example, in March, Advanced Organic Chemistry 368-69 (3rd Ed. 1985) and McManus et al., 3 Synth. Comm. 177 (1973), which is incorporated herein by reference. Appropriate compounds of formulas (2) and (2') can be obtained according to the method described in WO97/18205.

The amination agent, isobutylamine, can function also as a solvent, in this case, you can add the excess isobutylamine. In other embodiments, implementation of the method of amination is carried out in the presence of one or more solvents other than isobutylamine. In a preferred embodiment, the above-mentioned solvents used in the formation of compounds of the formulas (2) and (2').

In the embodiment of the invention, the amination reaction is carried out in the presence of about 15 equivalents of isobutylamine using toluene as solvent and heated to boiling under reflux at approximately 79°C.

The compound of the formula (3)

The compound of the formula (3) is obtained by introduction sulfonyloxy part, p-nitrobenzene-SO2in the intermediate product of the formula (2).

Thus, in the preferred embodiment, the compound of formula (3') can be obtained by sulfonylamine the compounds of formula (2').

As such, the haunted, compounds of the formulas (2) and (2') is subjected to reaction with sulfonylureas agent for making the compounds of formulas (3) and (3').

The term “sulfonyloxy agent” includes a p-nitrobenzenesulfonamide, such as p-nitrobenzenesulfonamide.

Treatment of compounds of formulas (2) and (2') sulfonylureas agent can be carried out in the presence of a solvent when heated from about 25°C to 250°C, preferably from 70°C to 100°C, and stirring. After sulfonylamine any remaining sulfonyloxy agent or its salt is preferably, though not necessarily, removed from the reaction mixture. This removal can be performed by repeated washing with water, the pH of the separation of organic and aqueous phase, ultrafiltration, reverse osmosis, centrifugation and/or filtration or the like.

The compound of the formula (4)

Compounds of the formulas (4) and (4') is obtained by restoring the nitro group of intermediate compounds of the formulas (3) and (3'), respectively, regenerating agent, optionally in an atmosphere of hydrogen.

Reducing agents suitable for nitrogroup reduction are a metal reducing reagent, such as complexes Baranov, DIBORANE, sodium borohydride, lithium borohydride, sodium borohydride-LiCl, whether yiluowadi or diisobutylaluminum; metals such as iron, zinc, tin and the like, and transition metals, such as palladium-on-charcoal, platinum oxide, Raney Nickel, rhodium, ruthenium and the like. When used catalytic reduction, as the source of hydrogen can be applied ammonium formate, sodium dihydrophosphate, hydrazine.

The compounds of formula (5)

The compound of the formula (5) is obtained by removing protection from intermediates of formula (4) and (4') in the conventional acidic conditions. Alternatively, you can apply the basic terms.

Remove aminosidine group can be performed using conditions that will not affect the rest of the molecule. These methods are well known in this field and include acid hydrolysis, hydrogenolysis, and the like, for example, using commonly known acids in suitable solvents.

Examples of the reagents and methods of removal from amines aminosidine groups can additionally be found in the publication Protective Groups in Organic Synthesis by Theodora W. Greene, New York, John Wiley and Sons, Inc., 1981, incorporated herein by reference.

As should be clear to the person skilled in the art, the choice aminosidine group used in the previous stage of the method, will determine the reagents and methods used to remove the specified aminosidine group.

Receiving darunavir

(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-ol of the formula (Ia), obtained as described above, appropriately activate agent combination with the formation of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-improving, which then carbamoylethyl compound of the formula (5) to obtain the desired inhibitor 1 protease, namely darunavir.

Examples of agents of the combinations used in the reactions carbamylcholine are carbonates such as bis-(4-nitrophenyl)carbonate, disuccinimidyl (DSC), carbonyldiimidazole (CDI). Other agents combinations include chloroformiate, such as p-nitrophenylphosphate, phosgene, such as phosgene and triphosgene.

In particular, when (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol is subjected to reaction with disuccinimidylsulfite, get 1-([[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yloxy]carbonyl]oxy)-2,5-pyrrolidinedione. The specified connection is preferred (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-alprozolam.

The reaction of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-improving with the compound of the formula (5) can be carried out in the presence of suitable solvents, such as tetrahydrofuran, dimethylformamide, acetonitrile, dioxane, dichloromethane or chloroform, and optionally with a base such as triethylamine, although also used additional to the munali abovementioned solvents and bases.

Among the solvents, preferred solvents are aprotic solvents, such as tetrahydrofuran, acetonitrile, dimethylformamide, ethyl acetate, and the like.

The above reaction carbamylcholine suitably carried out at a temperature from -70°C to 40°C, preferably from -10°C. to 20°C.

According to a particularly preferred feature of the present invention the inventors have proposed darunavir, that is, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-silt ether [(1S,2R)-3-[[(4-AMINOPHENYL)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]carbamino acid of the formula (A), is always synthesized using intermediate product of the formula (I) and especially the intermediate product of the formula (Ia)obtained according to the present invention.

Examples

There is a view that the following examples are an illustration of the present invention. These examples are presented to illustrate the invention in the form of examples and should not be construed as limiting the scope of the invention.

Gas chromatography (GC) was performed under the following conditions: column: 5% phenyl-, 95% methylpolysiloxanes, L=25 m; ID=320 μm; film width = 0,52 μm; injector with decomposition at 250°C with the ratio of 1/50; volume of injection: 1 µl. Program: 5 min at 50°C., then the heating rate 15°C/min to 240°C for 5 minobe flow: 3.0 ml/min The quality of the product of the reaction determines the percentage amount of the desired compounds in this product, determined by gas chromatography with flame ionization detection (FID) (% area GC).

In the following examples, “DCM“ refers to dichloromethane, “AcOEt” refers to ethyl acetate, THF refers to tetrahydrofuran and “TEMPO” refers to 1-oxide 2,2,6,6-tetramethylpiperidine.

Comparative example

(A) Acylhydrolase-(2-ethoxyacrylate-3-yl)acetate

To a mixture of freshly ethylglycol (40 mmol; 1,000 EQ.; 3,620 ml; 4,084 g) and 2,3-dihydrofuran (44 mmol; 1,100 EQ.; 3,338 ml; 3,084 g) in dry dichloromethane (100 ml; 1,560 mol; 132,5 g) was added dropwise a solution of titanium tetrachloride (44 mmol; 1,100 EQ.; 44,00 ml; 59,84 g) in 1 M DCM at -78°C and the resulting mixture was stirred for 1 h, the Reaction mixture becomes yellow and heterogeneous. To the mixture, which became heterogeneous, was added dropwise ethanol (120 mmol; 3,000 EQ.; 6,986 ml; 5,528 g). The cooling bath was removed to allow the reaction mixture to warm to room temperature over 1 h Slowly at room temperature was added sodium bicarbonate (100 ml; 103,4 mmol, 104,7 g). After 10 min the reaction mixture was extracted twice with ethyl acetate (600 ml; 6,132 mol; 540,2 g). The organic solvent evaporated under reduced pressure is, getting the green oil containing white solids (of 9.45 g, GC: area 14%).

GC: retention time: 13,4 minutes

MS (E 70 eV): 217 (0,5%; M-H); 173 (11%, M-OEt); 155 (59%, 173-H2O); 145 (21%, M-CO2Et); 71 (100%, 173-CHOCO2Et).

Determination of titanium in this crude mixture was carried out using the method ICP (inductively coupled plasma): 96 ppm titanium.

(C) Attempt recovery of the product from (A)

In a 50-ml round-bottom flask is loaded with ethanol (9.6 ml) and tetrahydroborate sodium (1.1 EQ.; 5.46 mmol, 210 mg) at 0°C dropwise over 1 h was added acylhydrolase-(2-ethoxyacrylate-3-yl)acetate (1.44 g; 4,96 mmol; 1 EQ.), dissolved in ethanol (5.8 ml). The reaction mixture is allowed to warm to room temperature and stirred for two days. Then to the reaction mixture at 0°C was added dropwise ammonium chloride (1.5 EQ.; 7,44 mmol; 400 mg)dissolved in water (3.5 ml). The reaction mixture was stirred for 4 h at room temperature and the solvent evaporated under reduced pressure, thus obtaining a brown solid. Then the crude mixture was added ethyl acetate (7.7 ml) and the mixture was heated at 40°C for 30 minutes After filtration through dicalite homogeneous mixture was evaporated to dryness under reduced pressure, thus obtaining the original substance.

Example 1

Eting is droxi-(2-isopropoxypyridine-3-furanyl)acetate

In a round bottom flask of 50% wt./mass. the solution acylglycerol in toluene (4,74 g, 23,21 mmol, 1.1 EQ.) was stirred under reduced pressure at 60°C until complete evaporation of the toluene. Then at room temperature was added 80 ml of dry DCM, followed by addition of TiCl2(OiPr)2(5 g, 21.1 mmol). After a period of stirring 0.5 h at room temperature dropwise over 10 min was added 2,3-dihydrofuran (1.48 g, 21.1 mmol, 1 EQ.), dissolved in 15 ml of DCM, and the mixture was stirred for 5 h at room temperature. Then was added dropwise isopropanol (16 ml, 211 mmol, 10 EQ.) and the mixture was stirred over night. Finally, at room temperature was added dropwise a basic aqueous mixture of Rochelle salt (20 g in 200 ml water, 2 g of Na2CO3) and the mixture was stirred over night. Two layers were separated and the organic layer was dried Na2SO4and concentrated in vacuum. The oil obtained (3,45 g, H.H.: the area of 85%) can be used directly in the next stage.

Determination of titanium: <5 ppm

MS (E.I. 70 eV): 173 (16%, M-OiPr); 159 (22%, M-CO2Et); 155 (100%, 173-H2O); 71 (98%, 173-CHOCO2Et).

MC (C.I., ammonia): (M+H)+: 233,1353 (theory: 233,1389); (M+NH4)+: 250,1593 (theory: 250,1654).

Example 2

Acylhydrolase-(2-isopropoxypyridine-3-furanyl)acetate

In a 1-liter round-bottom flask, the titanium tetrachloride (17,83 mmol; 1,96 ml; to 3.38 g) was dissolved in dichloromethane (70 ml; 1,092 mol; 92,75 g) at room temperature. Then at room temperature was added dropwise Tetra(isopropoxy) titanium (17,83 mmol; 5,28 ml 5,07 g)dissolved in dichloromethane (70 ml; 1,092 mol; 92,75 g). After a period of stirring 1 h for 30 min at room temperature was added dropwise ethylglycol (1.1 EQ.; 39,24 mmol; 3.55 ml; 4.0 g) without toluene, dissolved in dichloromethane (8,75 ml; to 136.5 mmol, 11,59 g). After 15 min during 30 min at room temperature was added 2,3-dihydrofuran (2.5 g; 1,000 EQ.; 35,67 mmol; 2,70 ml)dissolved in dichloromethane (17.5 ml; 273,0 mmol; 23,19 g). After a period of stirring 3 h was added dropwise isopropyl alcohol (10 equiv.; 356,7 mmol; 27,26 ml; 21,44 g). After 3 h, to the reaction mixture was added a mixture of potassium carbonate (1.75 g; 12,66 mmol) and Rochelle salt (17.5 g; 83,25 mmol)dissolved in water (175 ml; 9,72 mol, 175 g). After stirring for two days two layers were separated and the organic layer was washed (2×100 ml), water (200 ml; 11,10 mol; 200,0 g). The organic solvent evaporated under reduced pressure, thus obtaining the desired product (of 7.48 g; GC: 92% of the area).

Determination of titanium:

before processing Rochelle salt: 14,5%; after treatment Rochelle salt: <5 ppm

1H NMR (CDCl3 , 400 MHz): 5,23 (e, 0,42H, J=4 Hz); 5,20 (d, 0,48H, J=2 Hz); 5,16-5,08 (m, 0,14H); of 4.45 (d, 0,42H, J=4 Hz); 4,30-to 4.15 (m, 3H); 4,11-of 3.96 (m, 0,8H); 3,96-3,81 (m, 2,85H); 3,54 (user. C, 0,4H); 2,97 (user. C, 0,60H); 2,60-to 2.42 (m, 1,1H); 2,28-of 2.15 (m, 0,49H); 1,97-to 1.79 (m, 1,79H); of 1.30 (t, 3,8H, J=8 Hz); 1,24-to 1.21 (m, 0,46H); 1,21-of 1.16 (m, 3,12H); 1,16-of 1.12 (m, 3H).

13C NMR (CDCl3, 400 MHz): 174,1; 172,9; 103,9; 102,2; 70,2; 69,6; 69,4; 66,6; 61,9; 61,2; 49,9; 47,0; 25,1; 23,9; 23,7; 21,9; 21,7; 14,2.

Example 3

Acylhydrolase-(2-isopropoxypyridine-3-furanyl)acetate

In a 1-liter round-bottom flask, the titanium tetrachloride (17,83 mmol; 1,96 ml; to 3.38 g) was dissolved in dichloromethane (70 ml; 1,092 mol; 92,75 g) at room temperature. Then at room temperature was added dropwise Tetra(isopropoxy) titanium (17,83 mmol, 5,28 ml 5,07 g)dissolved in dichloromethane (70 ml; 1,092 mol; 92,75 g). After a period of stirring 1 h at room temperature during 30 min was added dropwise ethylglycol (1.1 EQ.; 39,24 mmol; 3.55 ml; 4.0 g) without toluene, dissolved in dichloromethane (8,75 ml; to 136.5 mmol, 11,59 g). After 15 min during 30 min at room temperature was added 2,3-dihydrofuran (2.5 g; 1,000 EQ.; 35,67 mmol; 2,70 ml)dissolved in dichloromethane (17.5 ml; 273,0 mmol; 23,19 g). After a period of stirring 3 h was added dropwise isopropyl alcohol (10 equiv.; 356,7 mmol; 27,26 ml; 21,44 g). After 3 h, to the reaction mixture was added a mixture of potassium carbonate (1.75 g; 12,66 mmol) and diethanolamine 9.5 g; 90,6 mmol)dissolved in water (175 ml; 9,72 mol, 175 g). After stirring for two days two layers were separated and the organic layer was washed (2×100 ml), water (200 ml; 11,10 mol; 200,0 g). The organic solvent evaporated under reduced pressure, thus obtaining the desired product (7.0 g; GC: 96% of the area).

Determination of titanium:

after processing diethanolamine: <5 ppm

Example 4

Acylhydrolase-(2-isopropoxypyridine-3-furanyl)acetate

In a round bottom flask loaded with 400 ml of DCM and Ti(OiPr)4(56,8 g, 0.2 mol)dropwise at room temperature over 30 min was added TiCl4(22 ml, 0.2 mol), dissolved in 400 ml of DCM. After a period of stirring 17 hours, dropwise at room temperature was added acylglycerol without toluene (45,2 g, 0.22 mmol, 1.1 EQ.), dissolved in 50 ml of DCM. After 15 min dropwise over 30 min was added 2,3-dihydrofuran (14 g, 0.2 mol, 1 EQ.), dissolved in 100 ml of DCM, and the mixture was stirred for 3 h at room temperature. Then added dropwise isopropanol (153 ml, 2 mol, 10 EQ.) and the mixture was stirred for 4 h at room temperature. Finally, was added dropwise a basic aqueous mixture of Rochelle salt (100 g in 1000 ml of water, 10 g of K2CO3) and the resulting mixture was stirred over night at room temperature. Two layers of abdelali and the organic layer was dried Na 2SO4, was filtered and was evaporated in vacuum. The oil obtained (47,2 g, GC: area 87%) can be used directly in the next stage.

GC: retention time: 13,7 minutes

MS (E.I. 70 eV): 173 (16%, M-OiPr); 159 (22%, M-CO2Et); 155 (100%, 173-H2O); 71 (98%, 173-CHOCO2Et).

MS (C.I., ammonia): (M+H)+: 233,1353 (theory: 233,1389); (M+NH4)+: 250,1593 (theory: 250,1654).

Example 5

Acylhydrolase-(2-isopropoxypyridine-3-furanyl)acetate

In a round bottom flask loaded TiCl(OiPr)3(0.1 mol, 1 M in hexane) and 300 ml of DCM is added dropwise at room temperature was added acylglycerol without toluene (22,6 g, 0.11 mol, 1.1 EQ.), dissolved in 25 ml DCM. After a period of stirring 0.5 h at room temperature dropwise at room temperature over 30 min was added 2,3-dihydrofuran (7 g, 0.1 mol, 1 EQ.), dissolved in 50 ml of DCM, and the mixture was stirred for 5 h at room temperature. Then at room temperature was added dropwise isopropanol (76 ml, 1 mol, 10 EQ.) and the mixture was stirred over night. Finally, dropwise at room temperature was added to the basic aqueous mixture of Rochelle salt (50 g in 500 ml of water, 5 g of K2CO3) and the mixture was stirred over night. Two layers were separated, the organic layer was dried Na2SO4, was filtered and was evaporated in vacuum. According to the scientists the oil (18.2 g, GC: the area of 85%) can be used directly in the next stage.

MS (E.I. 70 eV): 173 (16%, M-OiPr); 159 (22%, M-CO2Et); 155 (100%, 173-H2O); 71 (98%, 173-CHOCO2Et).

MS (C.I., ammonia): (M+H)+: 233,1353 (theory: 233,1389); (M+NH4)+: 250,1593 (theory: 250,1654).

Example 6

Acylhydrolase-(2-isopropoxypyridine-3-furanyl)acetate

In a round bottom flask loaded with 400 ml of DCM and Ti(OiPr)4(28.4 g, 0.1 mol)dropwise at room temperature over 30 min was added TiCl4(11 ml, 0.1 mol), dissolved in 400 ml of DCM. After a period of 17 h stirring dropwise at room temperature over 30 min was added acylglycerol without toluene (90 g, 0.44 mmol, 1.1 equiv.) dissolved in 150 ml of DCM. After 15 min dropwise during 30 min at room temperature was added 2,3-dihydrofuran (28 g, 0.4 mol, 1 EQ.), dissolved in 150 ml of DCM, and the mixture was stirred for 5 hours Then added dropwise at room temperature was added isopropanol (306 ml, 4 mol, 10 EQ.) and the mixture was stirred for 3 hours Finally, dropwise at room temperature was added to the basic aqueous mixture of Rochelle salt (100 g in 1000 ml of water, 10 g of K2CO3) and the mixture was stirred over night. Two layers were separated, the organic layer was dried Na2SO4, was filtered and was evaporated in vacuum. The oil obtained (81,5 g, GC: PL is under 70%) can be used directly in the next stage.

GC: retention time: 13,7 minutes

MS (E.I. 70 eV): 173 (16%, M-OiPr); 159 (22%, M-CO2Et); 155 (100%, 173-H2O); 71 (98%, 173-CHOCO2Et).

MS (C.I., ammonia): (M+H)+: 233,1353 (theory: 233,1389); (M+NH4)+: 250,1593 (theory: 250,1654).

Example 7

a) 1-(2-Isopropoxypyridine-3-furanyl)-1,2-ethanediol

A 2-liter round bottom flask loaded with 600 ml of ethanol and NaBH4(12,55 g, 0.33 mol, 1.1 EQ.) at 0°C dropwise over 1 h at 0°C was added acylhydrolase-(2-isopropoxypyridine-3-furanyl)acetate (70 g, 0.3 mol, 1 EQ.), dissolved in 400 ml of ethanol. The mixture was allowed to warm at room temperature and was stirred for 19 hours After cooling at 0°C was added over 10 min diethanolamine hydrochloride (46,7 g, 0.33 mol, 1.1 equiv.) dissolved in 100 ml of water, and the mixture was stirred for 8 hours, the Solvent is evaporated under reduced pressure, thus obtaining a light yellow solid. After dilution with 300 ml of ethyl acetate heterogeneous mixture was filtered through dicalite. The mixture was used directly in the next stage.

b) 1-(2-Isopropoxypyridine-3-furanyl)-1,2-ethanediol

In a round-bottom flask is loaded with ethanol (50 ml) and NaBH4(1,066 g, 28,19 mmol, 1.1 EQ.) at 0°C dropwise over 1 h at 0°C was added acylhydrolase-(2-from the propoxymethyl-3-furanyl)acetate (7,44 g, 25,62 mmol, 1.000 equiv.) dissolved in ethanol (30 ml). The mixture was allowed to warm to room temperature and was stirred for two days. Then to the reaction mixture at 0°C was added ammonium chloride (2,056 g, 38,44 mmol, 1.5 equiv.) dissolved in water (18 ml). The reaction mixture was stirred for 4 h at room temperature and the solvent evaporated under reduced pressure, thus obtaining a brown solid. Then the crude mixture was added ethyl acetate (40 ml) and the mixture was heated at 40°C for 30 minutes. After filtration through dicalite homogeneous mixture was evaporated to dryness under reduced pressure, thus obtaining the desired product (4,39 g, 19,61 mmol, 0,7655 EQ., output 76,55%).

Mixture of diastereomers:

1H NMR (CDCl3, 400 MHz): to 5.85 (d, J=8 Hz, 0,11H); 5,11-a 4.86 (m, 2H); from 4.3 to 3.6 (m, 7,7H); 3,8-3,5 (m, 3H); to 3.45 (m, 3,7H); 2,49-2,0 (m, 3,4H); 1,95-1,5 (m, 2,34); of 1.28 (m, 1,1H); 1,20-of 1.12 (m, 6H).

13C NMR (CDCl3; 100 MHz): (main peaks) 109,0; 108,2; 105,8; 105,5; 72,6; 69,6; 69,4; 67,8; 66,9; 63,3; 63,1; 63,0; 49,0; 48,7; 32,4; 28,9; 27,6; 26,4; 23,6; 21,8; 21,8; 15,2; 14,2.

GC: peaks of different isomers @ 5,7 min 17%; 6,07 min 8,29%; 6,32 min 15,7%; 6,7 min 20,29%; 6,9 min 11,0%; 10,6 min to 7.6%; min 10,8 5%.

Example 8

Hexahydrofuro[2,3-b]furan-3-ol

In a 50-ml round-bottom flask 1-(2-isopropoxypyridine-3-furanyl)-1,2-ethanediol (2,21 g; 8,89 mmol, 1 EQ.) was dissolved in tetrahydrofuran (9 ml). After about what ladenia at 0°C. to the mixture was added methanesulfonyl acid (65 mg; 676,33 Microm). The reaction mixture then was heated at 45°C for 30 min After cooling at room temperature, to the mixture was added triethylamine (0.3 g; 2,96 mmol). The solvent was evaporated and to the mixture at room temperature was added ethyl acetate (9 ml; 91,98 mmol). The mixture is then filtered through dicalite and the solvent was evaporated under reduced pressure, thus obtaining endo/Exo-bis-THF (1,562 g; GC: area 71%) when diastereomerism the ratio of endo/Exo-diastereoisomer 15/85.

Two diastereoisomers were separated by chromatography on silica gel, eluent: 9/1 mixture AcOEt/hexane.

GC: Exo-hexahydrofuro[2,3-b]furan-3-ol: retention time 11,36 min; endo-hexahydrofuro[2,3-b]furan-3-ol: retention time 11,57 minutes

1H NMR:

Exo-hexahydrofuro[2,3-b]furan-3-ol: to 1.67 (m, 1H); 2.13 in (m, 1H); 2,31 (user. s, 1H); and 2.79 (m, 1H); 3,8-3,9 (m, 3H); 2,95 (DD, 1H, J=3.2 Hz, J=10.3 Hz); 4,2 (d, 1H, J=3.1 Hz); at 5.9 (DD, 1H, J=4,9 Hz);

endo-hexahydrofuro[2,3-b]furan-3-ol: to 1.85 (m, 1H); 1,94 (user. s, 1H); and 2.27 (m, 1H); 2,84 (m, 1H); 3,6 (DD, 1H, J=7,1 Hz, J=9,2 Hz); the 3.89 (m, 1H); of 3.97 (m, 1H); 4,43 (DD, 1H, J=6,8 Hz, J=14,5 Hz); of 5.68 (d, 1H, J=5,2 Hz).

Example 9

a) Tetrahydrofuro[2,3-b]furan-3(2H)-he

In a 250-ml round-bottom flask NaOCl (x 6.15 g, 14% wt./mass.) was diluted in 100 ml of water. the pH of the solution was adjusted to 9.5 using 1 M aqueous solution of NaHCO3. In a separate 250-ml round-bottom flask is hexahydrofuro[2,3-b]furan-3-ol (1 g, 7.7 mmol, 1 EQ.) was dissolved in 15 ml of AcOEt at 0°C. Then was added KBr (91 mg, 0.77 mmol, 0.1 EQ.), dissolved in 1 ml of water, followed by addition of TEMRO (12 mg, 0.08 mmol, 0.01 EQ.). Finally, dropwise to the mixture was added NaOCl. After 15 min stirring at 0°C. the mixture was extracted with 3 times 100 ml of AcOEt. The collected organic layers were dried over Na2SO4and the solvent evaporated under reduced pressure, thus obtaining 950 mg of a white solid, yield: 96%. Formed tetrahydrofuro[2,3-b]furan-3(2H)-it was used in the next stage without additional purification.

The product was identified by exact mass: m/z 128,0473 (theoretical mass: 128,0473).

b) Stereoselective obtain (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol

In General, according to the method described by Ghosh et al. in J. Org. Chem. 2004, 69, 7822-7829, tetrahydrofuro[2,3-b]furan-3(2H)-he (950 mg, 7,42 mmol, 1 EQ.) was dissolved at 0°C in 50 ml of ethanol. In one portion to the mixture was added NaBH4(302,4 mg, 8 mmol, of 1.07 EQ.). After a period of stirring 1 h was added cleaners containing hydrochloride salt diethanolamine (3.2 g, 8 mmol, of 1.07 EQ.) and the mixture was stirred over night at room temperature. The heterogeneous mixture was filtered through dicalite and washed with 20 ml of hot AcOEt. After evaporation of the organic solvents under reduced pressure received 1500 mg hexahydrofuro[23-b]furan-3-ol with a yield (%) 40%; maximum output: 60%, diastereoisomeric excess: Exo-(3S,3aS,6aR)/endo-(3R,3aS,6aR): 18,5/81,5.

1. The method of obtaining the compounds of formula (V), which comprises reaction of 2,3-dihydrofuran formula (II) with a derivative of glyoxylate formula (III) in the presence of a titanium salt of the formula Ti(Hal)n(OR)4-nin which Hal represents a halogen radical, n is 0, 1, 2 or 3 and R represents an alkyl or arylalkyl, where aryl represents phenyl or naphthyl, and the subsequent reaction of the resulting reaction product with an alcohol of the formula (IV) with the formation of the compounds of formula (V):

where R1represents an alkyl or arylalkyl, where aryl represents phenyl or naphthyl, and R2represents an alkyl or arylalkyl, where aryl represents phenyl or naphthyl.

2. The method according to claim 1, in which the titanium salt is a compound of the formula Ti(Hal)n(OR)4-nin which n is 1, 2 or 3.

3. The method according to claim 1, in which R1represents a C1-4alkyl.

4. The method according to claim 1, in which R2represents a C1-4alkyl.

5. The method according to any one of claims 1 to 4, in which 2,3-dihydrofuran formula (II) is subjected to reaction with a derivative of glyoxylate formula (III) in the presence of a titanium salt and then the reaction product is subjected to reaction with an alcohol of the formula (IV) with the formation of compound Faure the uly (V).

6. The method according to any one of claims 1 to 4, in which the resulting reaction mixture containing the compound of the formula (V), treated with Rochelle salt to effect the removal of residual compounds titanium.

7. The method according to claim 6, in which the processing of Rochelle salt is carried out in an alkaline medium.

8. The compounds of formula (Va):

and their stereoisomeric forms and racemic mixtures,
in which R1represents an alkyl or arylalkyl, where aryl represents phenyl or naphthyl, and R2represents an alkyl or arylalkyl, where aryl represents phenyl or naphthyl, provided that when R2represents methyl, R1is not the stands or ethyl.

9. Acylhydrolase-(2-isopropoxypyridine-3-furanyl)acetate.

10. The method of obtaining compounds of formula (VI), which contains the recovery of the compounds of formula (V) with the formation of the compounds of formula (VI):

in which R1and R2have the meanings indicated in claim 1.

11. The method according to claim 10, in which the recovery is conducted borhydride regenerating agent.

12. The compounds of formula (VI):

in which R has the meanings indicated in claim 1.

13. 1-(2-Isopropoxypyridine-3-furanyl)-1,2-ethanediol.

14. The method of obtaining the compounds of formula (I)which provides the cyclization of compounds of formula (VI) with the formation of the compounds of formula (I):

15. The method according to 14, in which the cyclization of the compounds of formula (VI) carry out processing in a strong proton acid.

16. The method of obtaining hexahydrofuro[2,3-b]furan-3-ol of the formula (I), which contains the stage:
a) reaction of 2,3-dihydrofuran formula (II) with a derivative of glyoxylate formula (III) in the presence of a titanium salt of the formula Ti(Hal)n(OR)4-nin which n is 0, 1, 2 or 3 and R represents an alkyl or arylalkyl, where aryl represents phenyl or naphthyl, and the subsequent reaction of the resulting reaction product with an alcohol of the formula (IV) with the formation of the compounds of formula (V):

in which R1represents an alkyl or arylalkyl, where aryl represents phenyl or naphthyl, and R2represents an alkyl or arylalkyl, where aryl represents phenyl or naphthyl; and
(b) recovering the resulting compound of formula (V) with the formation of the compounds of formula (VI):

and
(C) cyclization of compounds of formula (VI) with the formation of the compounds of formula (I):

and, if desired, then (i) chiral separation of the formed compounds of formula (I) for separation of (3R,3S,6R)-hexahydrofuro[2,3-b]furan-3-ol of the formula (Ia):

and/or
(ii) the oxidation of the formed joint is of the formula (I) with the formation of the compounds of formula (I'):

and then restore the compounds of formula (I') in the compound of formula (Ia).

 

© 2013-2015 Russian business network RussianPatents.com - Special Russian commercial information project for world wide. Foreign filing in English.